星路科技發布全球領先RWA平台「FRP」 復星(00656.HK)升逾7%
復星國際(00656.HK)公布,旗下復星財富控股自主孵化的全球一站式Web5財富科技平台——星路科技昨日(23日)宣布正式啟動Web5戰略部署,並重磅發布其全球領先一站式RWA(現實世界資產)技術、發行及分銷平台——FinRWA Platform (FRP),開啟傳統金融與數字資產融合的新紀元。
復星財富控股行政總裁、星路科技董事長程康表示,復星財富控股與星路科技深耕香港財富管理市場,致力於推動傳統金融與數字金融的深度融合。隨著數字金融變革,星路科技的戰略構想可凝練為Web2+Web3=Web5這一創新等式。
復星近中午收市最新報5.4元,升7.57%,成交1.22億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.